|
Canadian Pharmacy |
|
|
|
 |
|
Laboratory Test Abnormalities
Increases in serum transaminase (ALT, AST) values and CPK have been observed.
Transient, asymptomatic eosinophilia has been reported. Eosinophil counts
usually returned to normal despite continued therapy. Anemia, thrombocytopenia,
and leukopenia have been reported with HMG-CoA reductase inhibitors.
Concomitant Therapy
Pravastatin has been administered along with cholestyramine, colestipol,
nicotinic acid, probucol and gemfibrozil. Preliminary data suggest that
the addition of either probucol or gemfibrozil to therapy with lovastatin
or pravastatin is not associated with greater reduction in LDL-cholesterol
than that achieved with lovastatin or pravastatin alone. No adverse reactions
unique to the combination or in addition to those previously reported for
each drug alone have been reported.
Myopathy and rhabdomyolysis have been reported when another HMG-CoA reductase
inhibitor was used in combination with immunosuppressive drugs, gemfibrozil,
erythromycin, or lipid-lowering doses of nicotinic acid. Concomitant therapy
with HMG-CoA reductase inhibitors and these agents is generally not recommended.
|
|
|
Pravachol Articles |
|
|
|
|
|
|
CUSTOMER SERVICE |
 |
 |
